The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 32 of the 40 sources its claims cite were checked for support.
Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience
Open accessAbstract
BACKGROUND: While age and the APOE ε4 allele are major risk factors for Alzheimer's disease (AD), a small percentage of individuals with these risk factors exhibit AD resilience by living well beyond 75 years of age without any clinical symptoms of cognitive decline. METHODS: We used over 200 "AD resilient" individuals and an innovative, pedigree-based approach to identify genetic variants that segregate with AD resilience. First, we performed linkage analyses in pedigrees with resilient individuals and a statistical excess of AD deaths. Second, we used whole genome sequences to identify candidate SNPs in significant linkage regions. Third, we replicated SNPs from the linkage peaks that reduced risk for AD in an independent dataset and in a gene-based test. Finally, we experimentally characterized replicated SNPs. RESULTS: Rs142787485 in RAB10 confers significant protection against AD (p value = 0.0184, odds ratio = 0.5853). Moreover, we replicated this association in an independent series of unrelated individuals (p value = 0.028, odds ratio = 0.69) and used a gene-based test to confirm a role for RAB10 variants in modifying AD risk (p value = 0.002). Experimentally, we demonstrated that knockdown of RAB10 resulted in a significant decrease in Aβ42 (p value = 0.0003) and in the Aβ42/Aβ40 ratio (p value = 0.0001) in neuroblastoma cells. We also found that RAB10 expression is significantly elevated in human AD brains (p value = 0.04). CONCLUSIONS: Our results suggest that RAB10 could be a promising therapeutic target for AD prevention. In addition, our gene discovery approach can be expanded and adapted to other phenotypes, thus serving as a model for future efforts to identify rare variants for AD and other complex human diseases.
Overview
CoChat Summary
TL;DR
This study used AD-resilient pedigrees, linkage, whole-genome sequencing, replication, and in vitro experiments to implicate rare RAB10 variation in protection against Alzheimer’s disease. The strongest evidence centered on rs142787485, which was associated with reduced AD risk and with lower Aβ42/Aβ40 after RAB10 knockdown.
Key findings
- Rs142787485 in RAB10 was associated with significant protection against AD (p = 0.0184, OR = 0.5853) and replicated in an independent unrelated series (p = 0.028, OR = 0.69); a gene-based test also supported RAB10 variants modifying AD risk (p = 0.002).
- Knockdown of RAB10 significantly decreased Aβ42 (p = 0.0003) and the Aβ42/Aβ40 ratio (p = 0.0001) in neuroblastoma cells, while RAB10 overexpression increased the Aβ42/Aβ40 ratio (p = 0.0133).
- RAB10 expression was significantly elevated in human AD brains (p = 0.04 in the abstract; Mayo Clinic temporal cortex Simple Model p = 6.96E-09, q = 1.50E-06).
- SAR1A did not replicate in the CCS (p = 0.26, OR = 0.87) and its gene-based test was not significant (p = 1.00); SAR1A functional results were inconclusive.
Methods
- Pedigree-based discovery: Utah Population Database pedigrees with excess AD mortality plus at least four AD-resilient individuals and four AD cases; linkage analysis with MCLINK identified suggestive peaks on chromosome 2 (TLOD 2.21) and chromosome 10 (TLOD 2.10).
- Samples and sequencing: 232 AD-resilient individuals from the Cache County Study (≥75 years, cognitively normal, ≥1 APOE ε4 allele; 135 females, 97 males, mean age 81), WGS for 212 at ~40×, plus 581 AD cases; validation used the Alzheimer’s Genetic Analysis Group, CCS, and ADNI, with SNP association and SKAT-O gene-based tests.
- Functional and expression work: RAB10 and SAR1A overexpression/knockdown in N2A695 cells with ELISA and immunoblotting; RNAseq expression analyses in 80 AD vs 76 control Mayo Clinic brains and public AD brain datasets.
Limitations
- The paper states that pedigree selection and rarity of AD-resilient samples made significant LOD scores difficult; only suggestive LOD scores were obtained in two of five pedigrees, with no significant LOD scores in any pedigree.
- The paper states that AD affection status relied on ICD9/ICD10 codes on Utah death certificates, which likely undercounts AD deaths and makes estimates conservative; genealogy data may include non-biological or censored relationships, and Utah European-descent results may not generalize.
- The paper states that SAR1A knockdown was only modest and its functional data were inconclusive; evident from the text, the discovery approach selected only one candidate SNP from each linkage peak for further analysis, and the SAR1A variant did not replicate.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
15 Valid · 9 Not valid · 3 Not checked · 76 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In neurons, RAB10 is involved in axonogenesis through the regulation of vesicular membrane trafficking toward the axonal plasma membrane [60].”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Discussion
What the sources say
- Could not verifycites [60] English AR, Voeltz GK. Rab10 GTPase regulates ER dynamics and morphology. Nat Cell Biol. 2013;15(2):169–78. sourceExperimental — accuracy not yet measured
The Abstract and Results describe Rab10 regulating ER tubule extension and fusion, including in Cos-7 cells, not axon formation in neurons. Searches for axonogenesis, neurons, and trafficking toward the axonal plasma membrane found no passage addressing the attributed claim. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“the majority of genetic variance is not explained by known AD markers [6]”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Background
What the sources say
- Supportedcites [6] Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, et al. Assessment of the genetic variance of late-onset Alzheimer’s disease. Neurobiol Aging. 2016;41:200. e213–220. source
The Discussion’s conclusions state that 69% of genetic variance remains unexplained by known AD risk variants. This directly supports the claim that the majority is not explained by known AD markers. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“and SAR1A expression is lower in neurons isolated from AD brains compared to controls [55].”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Discussion
What the sources say
- Could not verifycites [55] Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, Caselli RJ, Kukull WA, McKeel D, Morris JC, et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer’s disease: a reference data set. Physiol Genomics. 2008;33(2):240–56. sourceExperimental — accuracy not yet measured
The Results and Discussion section reports lower expression of several genes in AD neurons than in controls, but the passages found do not identify SAR1A among them. Searches for “SAR1A” and its gene description found no passage establishing the claimed decrease; the general AD-versus-control comparison does not verify this gene-specific claim. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“SAR1A binds APP [51]”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Discussion
What the sources say
- Could not verifycites [51] Olah J, Vincze O, Virok D, Simon D, Bozso Z, Tokesi N, Horvath I, Hlavanda E, Kovacs J, Magyar A, et al. Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein. J Biol Chem. 2011;286(39):34088–100. sourceExperimental — accuracy not yet measured
The Discussion describes binding between TPPP/p25 and Aβ42, not between SAR1A and APP. Searches for “SAR1A binds APP” and “SAR1A Sar1 amyloid precursor protein interaction” found no passage in our copy addressing the claimed binding. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a majority of remaining AD variants are likely to be rare [6, 8]”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Background
What the sources say
- Partly supportedcites [6] Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, et al. Assessment of the genetic variance of late-onset Alzheimer’s disease. Neurobiol Aging. 2016;41:200. e213–220. sourceExperimental — accuracy not yet measured
The Conclusions (section 4.1; page not provided) say that variants yet to be discovered are likely to be rare. They also say that a majority (69%) of genetic variance remains unexplained, but do not establish that a majority of the remaining variants, by number, are rare. (LLM, conf=0.83)
- Partly supportedcites [8] Ridge PG, Mukherjee S, Crane PK, Kauwe JS, Alzheimer’s Disease Genetics C. Alzheimer’s disease: analyzing the missing heritability. PLoS One. 2013;8(11):e79771. sourceExperimental — accuracy not yet measured
The Discussion says that remaining AD variants with large effects are likely to be very rare. It also anticipates additional common variants with small effects, and does not say that rare variants will constitute a majority of all remaining AD variants. Page numbers are not available in our copy. (LLM, conf=0.84)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 1 with their cited sources checked
Create a free account to see all 103 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 38
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rab10 and its phosphorylated form, pRab10 likely play a role in neurodegenerative diseases including Parkinson’s and Alzheimer’s diseases [64, 79, 94].”
From Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain (2023) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rab10 and its phosphorylated form, pRab10 likely play a role in neurodegenerative diseases including Parkinson’s and Alzheimer’s diseases [64, 79, 94].”
From Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain (2023) · cites this paper as [64]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a variant of Rab10 was identified as potentially protective in Alzheimer’s disease [64].”
From Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain (2023) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Ridge et al identified a rare variant (rs142787485) in the 3′-UTR of RAB10 that confers resilience to AD.10”
From RAB10: an Alzheimer’s disease resilience locus and potential drug target (2018) · cites this paper as [10]
In the citing paper
“More recently, iPSCs were successfully obtain from post-mortem human brain tissue, specifically dura mater fibroblasts91.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [91]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Results > Association with AD risk
“Both SNPs are rare, with 1000 Genomes minor allele frequencies of 0.0136 and 0.0168, for rs142787485 and rs7653, respectively.”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Results > Association with AD risk
“| rs142787485 | 2 | 26358156 | RAB10 | 3′ UTR | 0.041/0.028 | 0.0152/NA | | rs77747916 | 2 | 29405333 | CLIP4 | 3′ UTR | 0.0099/0.0069 | 0.0087/NA | | rs41291171 | 2 | 33623713 | LTBP1 | 3′ UTR | 0.049/0.049 | 0.0243/NA | | rs7653 | 10 | 71910316 | SAR1A | 3′ UTR | 0.03/0.0092 | 0.0175/NA |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Results > Over-expression and knockdown of RAB10 and SAR1A
“Rab10 expression does not significantly alter sAPP levels.”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Results > Over-expression and knockdown of RAB10 and SAR1A
“| RAB10 over-expression | sAPPbeta | 0.0187 | 0.1466 ± 0.04776 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Abstract > Methods
“Second, we used whole genome sequences to identify candidate SNPs in significant linkage regions.”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Discussion
“As a result, we obtained suggestive LOD scores in two of the five pedigrees, but no significant LOD scores in any of the pedigrees.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Discussion
“Approximately 50% knockdown of RAB10 resulted in a 45% reduction in Aβ42 levels (p value = 0.0003) and a 61% reduction in the Aβ42/Aβ40 (p value = 0.0001) ratio.”
§ Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience > Results > Over-expression and knockdown of RAB10 and SAR1A
“| RAB10 knockdown | Aβ42/Aβ40 | 0.0001 | −0.3876 ± 0.02243 |”
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Predicting effective microRNA target sites in mammalian mRNAs
Agarwal, V., Bell, G. W., Nam, J.-W., & Bartel, D. P. (2015) · eLife · doi:10.7554/elife.05005 · Cited by 7,318
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results
Lander, E., & Kruglyak, L. (1995) · Nature Genetics · doi:10.1038/ng1195-241 · Cited by 5,239
Research works printed but not linked: 2
- Skolnick M. The Utah Geneological database: a resource for genetic epidemiology. In: Cairns J, Lyons J, Skolnick M, editors. Banbury Report No 4: Cancer incidence in defined populations. New York: Cold Spring Harbor Laboratory Press; 1980. p. 285–97.
- Murray C. U.S. Patterns of mortality by county and race: 1965-1994. Cambridge: Harvard Center for Population and Development Studies; 1998.
Cited by
The multiplex model of the genetics of Alzheimer's disease
Sims, R., Hill, M., & Williams, J. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0599-5 · Cited by 466
Dhekne, H. S., Yanatori, I., Gomez, R. C., Tonelli, F., Diez, F., Schüle, B., Steger, M., Alessi, D. R., & Pfeffer, S. R. (2018) · eLife · doi:10.7554/elife.40202 · Cited by 240
Genetics of Alzheimer’s disease: where we are, and where we are going
Bellenguez, C., Grenier-Boley, B., & Lambert, J.-C. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.024 · Cited by 215
Novikova, G., Kapoor, M., TCW, J., Abud, E. M., Efthymiou, A. G., Chen, S. X., Cheng, H., Fullard, J. F., Bendl, J., Liu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21823-y · Cited by 214
Self-citationMicroglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211
Self-citation
Metadata
- Authors
- Initiative, F. T. A. D. N., Ridge, P. G., Karch, C. M., Hsu, S., Arano, I., Teerlink, C. C., Ebbert, M. T. W., Gonzalez Murcia, J. D., Farnham, J. M., Damato, A. R., Allen, M., Wang, X., Harari, O., Fernandez, V. M., Guerreiro, R., Bras, J., Hardy, J., Munger, R., Norton, M., Sassi, C., Singleton, A., Younkin, S. G., Dickson, D. W., Golde, T. E., Price, N. D., Ertekin-Taner, N., Cruchaga, C., Goate, A. M., Corcoran, C., Tschanz, J., Cannon-Albright, L. A., & Kauwe, J. S. K.
- Affiliations
- Brigham Young University (US)
- Washington University in St. Louis (US)
- Mayo Clinic (US)
- UCL Queen Square Institute of Neurology (GB)
- Utah State University (US)
- National Institutes of Health (US)
- Institute for Systems Biology (US)
- Corresponding author
- Kauwe, John S. K.
- ORCID
- Ridge, Perry G.
- Karch, Celeste M.
- Hsu, Simon
- Teerlink, Craig C.
- Ebbert, Mark T. W.
- Farnham, James M.
- Damato, Anna R.
- Allen, Mariet
- Wang, Xue
- Harari, Oscar
- Guerreiro, Rita
- Hardy, John
- Munger, Ronald
- Norton, Maria
- Sassi, Celeste
- Singleton, Andrew
- Dickson, Dennis W.
- Golde, Todd E.
- Price, Nathan D.
- Cruchaga, Carlos
- Goate, Alison M.
- Tschanz, JoAnn
- Venue
- Genome Medicine
- Published
- 2017-11-29
- Volume
- 9
- Issue
- 1
- Pages
- 100-100
- ISSN
- 1756-994X (ISSN-L)
- PMC
- PMC5706401
- OpenAlex
- W2768955389
- Cited by
- 83
- References
- 60
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 13 · 2023: 4 · 2022: 12 · 2021: 12 · 2020: 14 · 2019: 9 · 2018: 9
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-01-12)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Genome Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, other-oa)
- University of Florida Digital Collections (University of Florida) (submittedVersion, other-oa)
- Digital Commons - USU (Utah State University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute on Aging (RF1AG054052, U01AG052411)
- National Institute of Neurological Disorders and Stroke (R01NS080820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, Rab10, genetic linkage, rare variants, APOE ε4, amyloid-beta 42, Aβ42/Aβ40 ratio, neuroblastoma cells, gene knockdown, therapeutic target
- MeSH terms
- Aged, 80 and over, Alzheimer Disease, Animals, Brain, Female, Humans, Male, Gene Expression, Genetic Predisposition to Disease, Monomeric GTP-Binding Proteins, Polymorphism, Single Nucleotide, rab GTP-Binding Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience. https://app.cochat.ai/papers/10.1186/s13073-017-0486-1
- The paper
- Initiative, F. T. A. D. N., Ridge, P. G., Karch, C. M., Hsu, S., Arano, I., Teerlink, C. C., Ebbert, M. T. W., Gonzalez Murcia, J. D., Farnham, J. M., Damato, A. R., Allen, M., Wang, X., Harari, O., Fernandez, V. M., Guerreiro, R., Bras, J., Hardy, J., Munger, R., Norton, M., . . . Kauwe, J. S. K. (2017). Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience. Genome Medicine. https://doi.org/10.1186/s13073-017-0486-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.